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divided into 4 subgroups (Table). Conclusion: Measuring the combination of TnT and 
BNP after optimized treatment may be valuable for risk assessment of cardiac mortality 
and morbiditv in CHF pts. 
-Risk etr&cation using discharge values of TnT and BNP 
Subgroup I (T-/8-) n=37 II (l-/B+) n=20 Ill (T+/B-) n=9 IV (T+/B+) n=27 
Cardiac death 0 (0%) 0 (0%) 2 (22%) 7 (26%) 
Cardiac event 5 (14%) 6 (30%) 4 (44%) 21 (78%) 
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1015-137 Compensated Cardiac Hypertrophy in Endothelial Nitric 
Oxide Synthase Knockout Mice 
Michael P. Fl&&y, Maria Brown, Hitoshi Takano, lngrid L. Grupp, Jo El Schultz, Sidney 
Murphree, W. Keith Jones, University of Cincinnati, Cincinnati, Ohio, University of 
Louisville, LouisviNe. Kentucky 
Background’. It is well documented that endothelial nitric oxide synthase (eNOS) homozy- 
gous knockout mice (eNOS+) develop sustained arterial hypertension. Because of con- 
troversy over the development of cardiac pathophysiology in these mice, we undertook to 
investigate the cardiac functional and biochemical affects of chronic eNOS ablation. 
Methods: We examined steady state levels of molecular markers of cardiac hypeltrophy 
and heart failure in male eNOS.” and control mice at 18-20, 27-30, 40 and 52 weeks of 
age. Histological examination at 40 weeks of age and cardiac functional analysis using 
the isolated work performing heart preparation were perlormed at 52 weeks of age. 
Results: Hearts from eNOS+ mice exhibited concentric left ventricular hypertrophy, multi- 
focal replacement fibrosis and evidence of myocyie degeneration/death. As mice aged, 
re-induction of atrial natriuretic factor (ANF) and a-skeletal-actin mRNA correlated posi- 
tively with the degree of cardiac hypertrophy. Significant increases in cardiac expression 
of tumor necrosis factor-a (TNF-a) mANA and protein were detected at 27-30 weeks. 
Sarcoplasmic reticulum Ca’+-ATPase (SERCA2a) transcript levels were markedly 
decreased at 27-40 weeks, whereas heads of eNOS”- mice 52 weeks of age demon- 
strated normalized SERCA2a and slightly decreased phospholamban protein levels. 
Although hearts of eNOS’. mice at 52 weeks of age demonstrated no deficit of baseline 
function, there was a blunted response to P-adrenergic stimulation indicative of reduced 
contractile reserve. 
Conclusions: Although eNOS+ mice exhibit myocardial remodeling, including re-induc- 
tion of cardiac fetal genes and dysregulation of TNF-a and SERCA2a, there is no pro- 
gression to failure before 52 weeks of age and in fact these hearts are hypercontractile. 
An increased ratio of SERCA2a protein to phospholamban protein at this timepoint sug- 
gests a mechanism for the long-term physiological compensation that occurs in eNOS”. 
hearts. 
1015-138 New Mutation in Lamin A/C Gene Associated With 
Severe Dilated Cardiomyopathy 
B. Lorenzo Monserrat, Sandra Barral, Rafael Laredo, Beatriz q  ouzas, 
Marisa Crespo. Alfonso Castro-Beiras, Hospital Juan Canalejo, A Corufia, Spain, 
lnstituto de Ciencias de la Salud, A Corufia, Spain. 
Background: Idiopathic Dilated Cardiomyopathy (DCM) is familial in about 30% of the 
cases. Lamin AJC mutations have been identified for causing familial DCM, frecuently 
associated with conduction system disease. We repon here a novel lamin A/C mutation 
with features of severe dilated cardiomyopathy. 
Methods: After informed consent, we studied the lamin A/C gene in 17 patients of 14 dif- 
ferent families with familial DCM. DNA was isolated from frozen blood samples and cod- 
ing regions of lamin A/C were PCR amplified, studied by SSCP and cycle sequenced. 
Results:Three members of one of the families (mother and her two female identical 
twins) developed severe DCM and required cardiac transplantation at 36, 18, and 20 
years old respectively. The father of the index case had died suddenly at 52 years old. At 
diagnosis, the mother was on atrial fibrillation with slow ventricular response. No conduc- 
tion disturbance was present in the twins. 
A new mutation (Arg349Leu) was identified in exon 6 in the three patients. This mutation 
was not present in 22 unaffected relatives and in more than 100 healthy controls. This 
mutation affects a highly conserved region identical in Xenopus laevis. Gallus gallus. 
Rattus norvegicus and humans. 
Conclusions: The Arg349Leu mutation in LMNA A/C gene is associated with a severe 
form of DCM. 
1015-139 Cyclosporine A Treatment Decreases Left Ventricular 
Mass in Mice Expressing a FHC-Linked Troponin T 
(179N) Mutation 
Bioern C. Knollmann, Syevda G. Sirenko, James D. Potter, Kenneth Horton, Neil J. 
Weissman, Georgelow Universify School of Medicine, Washington, Dist. of Columbia, 
Washington Hospital Center, Washington, Dist. of Columbia. 
Cyclosporine A (CyA) prevents cardiac hypertrophy in several animal models, and has 
been proposed as treatment for Familial Hypertrophic Cardiomyopathy (FHC). But with 
the recent report that CyA administration increased cardiac hypertrophy and mortality in 
a mouse model of FHC (aMHC+/403), proposed clinical studies with CyA were aban- 
doned. Because the CyA effect could be specific to this particular mouse model, we 
examined the effect of CyA in a different murine FHC model expressing a troponin T 
(179N) mutation. Methods: Mice expressing human wild-type (Tg-WT), mutant (Tg-l79N) 
Troponin T and non-transgenic littermates (Non-Tg) were treated with CyA (18mqkgl 
day) or vehicle for 4 weeks. LV dimensions, mass and function were measured with 
serial echocardiography in blinded fashion. Results: All mice tolerated CyA treatment. 
LV wall thickness and mass significantly decreased in CyA-treated Tg-l79N mice corn- 
pared to all other groups (table). Systolic function was unchanged. On sacrifice, heart to 
body weight ratio was significantly decreased in CyA-treated compared to vehicle-treated 
Tg-l79N mice, (3.3ztt.lmg/S vs. 3.6M.lmg/g. pc.05). No significant differences in tissue 
histology were found. Blood CyA levels were 453+124 nglml. Conclusion: Unlike in 
mice expressing a a-myosin heavy chain FHC mutation, CyA treatment reduced LV 
mass in mice expressing a FHC-linked Troponin T mutation. Thus, any effect of CyA 
treatment should not be generalized across different FHC-linked mutation or models. 
Effect of CyA treatment on LV-mass (means+ee) 
Genotwe n Treatment Baseline (ma) 4 weeks (ma) 
Tg-l79N 
Tg-l79N 
Tg-WT 
Non-Ta 
7 CYA 84t3 72+4” 
7 Vehicle 85t6 116*4 
6 CYA 1 oot3 11255 
6 CvA 67*3 111*6 
1015-140 Effect of Estrogen on Angiotensin Receptors, Matrix 
Metalloproteinases, and Left Ventricular Mass in a 
Transgenic Mouse Model of Human Hypertrophic 
Cardiomyopathy 
Edith Speir, zurxiylc, Kazuyo Takeda, Victor J. Ferrans. Mariappan Muthuchamy, Lameh 
Fananapazir, National Heart, Lung and Blood Institute, Bethesda, Maryland, Texas ABM 
Univarsify, Co//ege Station, Texas. 
Background: Mutahons in a-tropomyosin (Aspl75Asn) can cause familial hypertrophic 
cardiomyopathy (FHCM). Estrogen has been shown to be cardioprotective in several dis- 
eases. This study was designed to determine whether estrogen in physiological doses 
can modify left ventricular (LV) function and hypertrophy by attenuating release of matrix 
metalloproteinases (MMPs) and by regulating angiotensin receptors (AT,) in a transgenic 
mouse model (TGM) expressing Aspl75Asn. 
Methods: TGM and nontransgenic cohorts (NTGM) (20 each) were ovariectomized (0~). 
Slow-release (90 days) estrogen pellets were implanted in 10 mice of each group; the 
other 10 received placebo. Echocardiograms were performed in awake mice at 2 weeks 
after ov (baseline) and after 3 months of daily treadmill exercise. LV mass was assessed 
from M-mode tracings. Mice were then euthanized and some hearts were perfusion-fixed 
and embedded in paraffin, for sectioning; others were processed for frozen sections and 
tissue extracts. lmmunohistochemical staining and immunoblotting were performed. 
Results: Intact TGM and NTGM had LV masses of 77 and 49 mg. and placebo-treated 
and estrogen-treated OY TGM had LV masses of 79 and 60 mg. respectively (p-zO.05, for 
both comparisons). AT-1 receptors, MMP-3 and MMP-13 were increased in untreated ov 
TGM compared to estrogen-treated OY TGM. 
Conclusions: Estrogen replacement significantly reduced LV mass, AT-1 receptors and 
MMP-3 and MMP-13 in a model of FHCM. These findings suggest that estrogen can reg- 
ulate expression of genes involved in matrix metabolism and cardiac fibrosis, which are 
of clinical importance in human patients with FHCM. 
1015-l 59 Determinants of Exercise Capacity in Hypertrophic 
Cardiomyopathy: The Role of Left Ventricular Outflow 
Tract Obstruction 
MunmohanS.Virdee, Yoshihisa Matsumura, Sami Firoozi, Perry M. Elliott, William J. 
McKenna, St George’s Hospital Medical School, London, United Kingdom. 
Background: The influence of left ventricular outflow tract obstruction (LVOTO) on exer- 
cise capacity in patients (pts) with Hypertrophic Cardiomyopathy (HCM) is poorly under- 
stood. 
Methods: 86 pts with HCM (43 +14yrs, 73% symptomatic) underwent upright bicycle 
ergomehy with expiratory gas analysis and echocardiography. Oxygen consumption at 
peak exercise (pkVOP), anaerobic threshold (atV02); 02 pulse at peak exercise (pkO2 
pulse), anaerobic threshold (at02 pulse); and peak workload are expressed as percent- 
age of predicted values. 
Results: 37 pts with resting LVOTO >=30mmHg (58 *2OmmHg, group A), had a lower 
pkVO2 than those without resting LVOTO, 65 219 vs 74 *19%, p=O.O3. In pts without 
resting LVOTO, pkVO2 correlated with peak exercise LVOTO (wO.43, p=O.O03) and 
change in LVOTO during exercise (r=O.44, p=O.O02). Of 49 pts without resting LVOTO. 
16 developed LVOTO >SOmmHg during exercise (group Bi), 33 did not (group Bn). Peak 
exercise LVOTO was lower in group Bi than group A (48 i21 vs 81 r27mmHg. p<O.OOl). 
Table 1. 
There was no difference between the 3 groups for peak heart rate and respiratory quo- 
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tier0 at peak exercise. PkVOP correlated with percent change in heart rate after anaero- 
bic threshold in groups A (rxO.45, p=O.O07) and Bn (r=O.67, p<O.OOl) only. 
Conclusions: P1s with resting LVOTO have poorer indices of cardiac function/exercise 
capacity. Non-obstructive HCM pts with exercise-induced LVOTO have cardiopulmonary 
indices consistent with better stroke volume augmentation during exercise. 
Table 1. Comparison of exsrcise parameters between the three groups. 
1015-162 Prediction of Sudden Death in Patlents With Dilated 
Cardiomyopathy Receiving Angiotensin Converting 
Enzyme Inhibitors and Beta-Blockers: The Extent of 
intercellular Myocardial Fibrosis and the Presence of 
Nonsustained Ventricular Tachycardia 
March 6,2002 
Takahisa Yamada. Masatake Fukunami. Tsuyoshi Shimonagata, Kazuaki Kumagai, Akio 
Hirata, Mitsutoshi Asai, Nobuhiko Makim, Hidetaka Kioka, Noritake Hoki, Osaka 
Prefectural General Hospital, Osaka, Japan. 
Background: Recent clinical trials have shown that angiotensin-converting enzyme 
inhibitors (ACEI) and beta-blockers (BE) reduce the mortality in patients with dilated car- 
diomyopathy (DCM). However, some DCM patients still died suddenly in spite of the 
administration of ACEI and BB. We tried lo identify patients at risk for sudden death in 
DCM patients receiving ACEI and BB. Methods: We studied 50 DCM patients (NYHA 
class: 2.6M.6, left ventricular ejection fraction: 32+6%) receiving ACEI (76%) and BB 
(76%). At the baseline, we performed echocardiography, 24 hour Halter monitoring, right 
side cardiac catheterization, left ventricular endomyocardlel biopsy. The extent of myo- 
cardial fibrosis was estimated by the point count method in all biopsy samples. Moreover, 
after classifying myocardial fibrosis separately into two types, intercellular (IC) and inter- 
fascicular fibrosis, by the distribution of fibrosis on each cross point, we also estimated 
the extent of each fibrosis. 
Results: During the observation period of 56ti6 months, 8 patients died suddenly. By 
multivariate Cox analysis, out of the variables including clinical, hemodynamic. echocar- 
diographic parameters, the presence of nonsustained ventricular tachycardia (VT: more 
than 5 consecutive ventricular ectopic beats) and the extent of myocardial fibrosis, the 
extent of IC fibrosis (p=O.O05) and the presence of nonsustained VT (p=O.O4) were inde- 
pendently associated with sudden death. Kaplan-Meier analysis revealed that patients 
with a greater extent of IC fibrosis (~-12.5%) and nonsustained VT (Group I) showed sig- 
nificantly higher rate of sudden death than those with a lesser extent of IC fibrosis or the 
absence of nonsustained VT (Group II) (67% vs 9%, p<O.OOOl). 
Conclusion: The extent of IC fibrosis and the presence of nonsustained VT would be a 
powerful predictive marker for sudden death in DCM patients receiving ACEI and 99. 
Peak Workload 
pkVO2 
pk02 pulse 
atVO2 
at02 pulse 
GROUP A p(A v Bi) GROUP Bi p(Bi v Bn) GROUP Bn 
62 zt23 <O.OOl 67 +21 0.003 67+19 
65 +I9 <0.001 65*16 0.002 66 +I7 
62 +I9 0.003 99*18 0.004 62 +I9 
35~12 0.007 44 *I3 “s 39 *9 
59 *20 0.006 74 *I8 “S 64215 
1015160 Quantification of Myocardial Injury After Percutaneous 
Transluminal Septal Myocardial Ablation in 
Hypertrophlc Obstructive Cardiomyopathy 
m, Folkerl J. ten Cab?, Jurrien M. ten Berg, Aernout M. Beck, Albert 
C. van Rossum, VU University Medical Center, Amsterdam, The Netherlands. 
Background: Percutaneous transluminal septal myocardial ablation (PTSMA) is a non- 
surgical therapeutic procedure for reducing len ventricular outflow tract obstruction in 
symptomatic patients with hyperlrophic obstructive cardiomyopathy (HOCM). The aim of 
this study was to evaiuale septal myocardial injury size aner PTSMA using delayed con- 
trast-enhanced (DCE) magnetic rssonancs imaging (MRI). 
Methods: 12 patients (mean age 52*15 years, 7 males) underwent MRI before and 4 
weeks after PTSMA: volume of ethanol injected during procedure was 1 to 5 mL. Images 
were acquired on a 1.5 T scanner (Vision/Sonata, Siemens, Erlangen. Germany). Cine 
gradient-echo MRI was performed for assessment of global I& ventricular function at 
baseline and follow-up. Inversion-recovery turbo-FLASH images (TE 3.4 ms. TR 7.6 ms, 
TI 250-300 ms) were acquired at follow-up, 20 to 30 minutes after i.v. administration of 
0.2 mmolikg gadolinium-DTPA. Left ventricular function parameters, myocardial mass, 
and hyperenhanced area’s (including central dark zones of hypoenhancement) were 
quantified using the MASS software package (Leiden University Medical Center, the 
Netherlands). 
Results: Lefl ventricular mass values before and after PTSMA were 235.6 * 70.7 g vs. 
225.2 * 71.7 g (p=O.OOl), respectively. Septal myocardial mass pre- and post PTSMA 
were 79.2 * 29.4 g vs. 72.7 * 26.2, resp. In all patients the injured myocardium was well 
visualized. The hyperenhanced septal myocardial mass was in the range of 3.6 to 24.9 g 
[mean: 12.6 * 7.6 g], and involved 5.0 % f 4.0 of the post-ablational total LV mass vs. 
21.2 % * 16.0 of the septal myocardial mass. Myocardial injury size was not correlated 
with the volume of ethanol administered. 
Conclusions: The extent of myocardial injury after PTSMA can be determined using 
DCE-MRI and was not correlated with the volume of ethanol administered. The method 
may serve as control and feedback for the interventional procedure. 
1015-161 Untoward Effect of Septal Reduction Interventions on 
Conduction System in Patients With Obstructive 
Hypertrophic Cardiomyopathy 
,!ian Xin Qin, Takahiro Shiota, Harry M. Lever, Neil L. Greenberg, Deborah A. Agler, 
Jeanne K. Drinko, Maureen Martin, Maura J. Schnauffer, Nicholas G. Smedira, E. Murat 
Tuzcu, Bruce Lytle. James D. Thomas, The C/eve/and Clinic Foundation, Cleveland, 
Ohio. 
Hypertrophic obstructive cardiomyopathy (HOCM) patients may develop conduction 
abnormalities after percutaneous transluminal septal myocardial ablation (PTSMA) and 
myectomy (MYE) procedures. The aim of the study was to observe the impact of both 
procedures on the conduction system. Methods: A total of 101 HOCM patients without 
preexisting permanent pacemaker were enrolled in this study. 55 patients were included 
in MYE and 46 patients in PTSMA group. Standard 12 leads ECGs were acquired before 
and 3-month after the procedures. Doppler echo was used to quantify the LVOT pressure 
gradient (PG). Results: Both PTSMA and MYE significantly reduced the LVOT PG (66 f 
41 vs 29 ? 26 mmHg for PTSMA and 66 * 44 YS 14 f IO mmHg for MYE, both p < 
0.0001). Aner PTSMA, a permanent pacemaker was implanted in 13 (26%) patients. 20 
patients developed new complete right bundle branch block (CRBBB). After MYE, 6 
(11%) patients required permanent pacemakers (p-=0.05 vs PTBMA) while 36 patients 
developed complete left bundle branch block (CLBBB) (table). 
N Pacer CRBBB CLBBB 
Pre Post Prs POSt 
PTSMA 46 13 (26%) 3 (7%) 23 (70%) 0 (0%) 2 (2%) 
MYE 55 6 (11%)’ 0 (0%) 0 (O%)T 3 (5%) 41 (64%)t 
MYE vs PTSMA, * p-z 0.05, t p < 0.0001. 
5 PTSMA patients required subsequent myectomy because of incomplete relief of the 
PG. 4 of them needed permanent pacemakers. Conclusion: Both F’TSMA and MYE sig- 
nificantly reduced LVOT PG. However, right branch bundle block was frequently pro- 
duced by PTSMA and left branch bundle block was often caused by MYE. Severe AV 
block may develop when both procedures are required. 
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1016-141 QT Dispersion Is Not Associated With Left Ventricular 
Function in Elderly Patients With Symptomatic Heart 
Failure: ELITE II Substudy 
Y~_G~QQ, Takuya One, Katerina Hnatkova, Kenich Hashimoto, A. John Camm, Berlram 
Pin, Philip A. Poole-Wilson, Frederic Sax, Kathryn Bohannon. Marek Malik. for ELITE II 
investigators, St. George’s Hospital Medical School, London, United Kingdom, Merck 
Research Laboratories, West Point, Pennsylvania. 
Background It remains controversial if QT dispersion (QTd) is associated with left ventric- 
ular function or aetiology in patients (pts) with hearl failure (HF). 
Methods To examine the &.ociation behveen QTd and left ventricular function and the 
prognostic value of QTd in HF secondary either to idiopathic dilated cardiomyopathy 
(IDC) or ischaemic heari disease (IHD), we studied 966 HF pts (age 71?7 year, 703 men) 
enrolled into the ELITE II trial. Of study pts, 766 had IHD (age 71i7 years, 573 men) and 
105 had IDC (age 7lt7 years, 65 men). QT intervals were manually measured on stan- 
dard IP-lead ECGs using an in-house computer assisted system. 
Results In all study pts, the mean QTd and JTd were 66i31 and 62i32 ms, respectively. 
In pts with LVEF<25%, heart rare was significantly higher (PcO.0001) and QT was signif- 
icantly shorter (~25% (66+31 Y 66i31 ms). No significant difference in QTd was found 
between pts with and without NYHA class III-IV either (67i31 Y 64f32 ms). QTd was not 
correlated with LVEF (r= -0.0004) or NYHA (r= -0.04). During follow-up (54til53 days), 
119 (12%) pts died of cardiac cause (CD), including 59 (6%) sudden death (SD). A pro- 
spective cut-off value at QTd>60 ms failed to identify pts with CD or SD, while signifi- 
cantly more patients with LVEF<25% died of CD than those with LVEF>25% (16% v II%, 
p=O.O45). There were no significant differences in age and NYHA functional class 
between IHD and IDC. More male (75% v 62%. p=O.OOS) and higher LVEF (31.6k6.6 v 
26.2+7.1%, p<O.OOl) were found in IHD than IDC. The mean QTd in IHD were similar to 
IDC (66+32 v 67i27 ms) and it was not related to mortality at all. The frequency of CD or 
SCD were not significantly different in IDC and IHD (II%, 6% v 13%, 6%, respectively, 
p=NS). In both IHD and IDC, a QTd >60ms failed to predict CD or SCD. The results 
remained unchanged when JTd was analysed in the same manner. 
Conclusions In this ELITE II substudy, QTd (and JTd) was neither associated with len 
ventricular function. nor with aetiology of heart failure. Reduced LVEF remains a slgnifi- 
cant predictor of CD but increased QTd did not predict mortality irrespective of aetlology 
of HF. 
